Bosutinib [BOS1]
Bosutinib for previously treated chronic myeloid leukaemia
- I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
- I confirm the patient has chronic, accelerated or blast phase Philadelphia chromosome positive chronic myeloid leukaemia.
- I confirm the patient has had previous treatment with 1 or more tyrosine kinase inhibitor.
- I confirm that treatment is not appropriate with either imatinib, nilotinib or dasatinib.
- I confirm the patient will receive the licensed dose and frequency of bosutinib
NHS funded From: 22 November 2016
Additional information
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.